CYL Stock Chart & Stats
€31.20
€0.20(0.72%)
At close: 4:00 PM EST
€31.20
€0.20(0.72%)
Day’s Range― - ―
52-Week Range€17.40 - €41.10
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€1.00B
Enterprise Value€1.23B
Total Cash (Recent Filing)€55.76M
Total Debt (Recent Filing)€258.16M
Price to Earnings (P/E)94.1
Beta0.45
Next Earnings
Jul 30, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding48,543,350
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.19Price Target Upside19.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.08
Revenue Forecast (FY)€426.51M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth across 2021–TTM shows expanding procedure adoption and commercial traction across product lines. Durable revenue expansion supports scale, better fixed-cost absorption, and funds R&D and commercialization investments over the next several quarters.
Return To Profitability & Margin ProgressTransition from loss-making to positive operating profit indicates improving unit economics and cost control. A recurring positive operating margin provides a foundation for predictable EBITDA generation and incremental reinvestment or deleveraging over the medium term.
Strategic Acquisition Strengthens Product PortfolioOwning NEXUS and integrating Endospan expands addressable markets and differentiates Artivion in aortic arch solutions. FDA approval and portfolio breadth create structural commercial advantages and future revenue optionality as U.S. launch and cross-selling scale.
Bears Say
Thin Net Margins & Uneven Free Cash FlowLow net margins and historically volatile free cash flow limit the company’s cushion against shocks and reduce capacity to fund organic growth or absorb integration costs. Persistent thin profitability constrains capital allocation flexibility over the coming quarters.
AMDS Starter-set Adoption DelaysOperational and administrative adoption barriers slow initial account conversions and delay creation of recurring implant/reorder revenue. If institutional procurement hurdles persist, it will mute the durable ramp in a key growth product for several quarters.
Acquisition-related Near-term Earnings And Interest PressureDeal financing and integration costs compress near-term adjusted EBITDA and raise interest expense, slowing deleveraging. The incremental load and contingent considerations reduce free cash flow headroom and increase execution risk during the integration period.
CYL FAQ
What was Artivion Inc.’s price range in the past 12 months?
Artivion Inc. lowest stock price was €17.40 and its highest was €41.10 in the past 12 months.
What is Artivion Inc.’s market cap?
Artivion Inc.’s market cap is €1.00B.
When is Artivion Inc.’s upcoming earnings report date?
Artivion Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Artivion Inc.’s earnings last quarter?
Artivion Inc. released its earnings results on May 07, 2026. The company reported €0.026 earnings per share for the quarter, beating the consensus estimate of €0.023 by €0.004.
Is Artivion Inc. overvalued?
According to Wall Street analysts Artivion Inc.’s price is currently Undervalued.
Does Artivion Inc. pay dividends?
Artivion Inc. does not currently pay dividends.
What is Artivion Inc.’s EPS estimate?
Artivion Inc.’s EPS estimate is <0.01.
How many shares outstanding does Artivion Inc. have?
Artivion Inc. has 48,543,350 shares outstanding.
What happened to Artivion Inc.’s price movement after its last earnings report?
Artivion Inc. reported an EPS of €0.026 in its last earnings report, beating expectations of €0.023. Following the earnings report the stock price went down -11.486%.
Which hedge fund is a major shareholder of Artivion Inc.?
Currently, no hedge funds are holding shares in DE:CYL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€37.19 (19.21% Upside)
€37.19 (19.21% Upside)
Blogger Sentiment
Bullish
DE:CYL Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.24%
12-Months-Change
Fundamentals
Return on Equity
2.66%
Trailing 12-Months
Asset Growth
11.63%
Trailing 12-Months
Company Description
Artivion Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
CYL Company Deck
CYL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally constructive long-term story—double-digit revenue growth, strong adjusted EBITDA expansion, margin improvement, encouraging product-level performance (notably On-X and tissue processing), rapid deleveraging, and a strategic acquisition (Endospan/NEXUS) that completes a differentiated aortic arch portfolio. Near-term execution challenges—lower-than-expected AMDS starter-set conversions, regional softness (Middle East), targeted supply-chain constraints, and a moderated full-year guidance—tempered the immediate outlook. Management provided clear remediation plans (value analysis committee work, programs to reduce the upfront AMDS burden, inventory and hiring plans for NEXUS) and maintained multi-year pipeline catalysts (ARTISON, C-Branch LSA) that support future upside.View all DE:CYL earnings summariesCYL Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€37.19
▲(19.21% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---









